Compare Biogen Inc (BIIB) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Manulife Financial Corporation — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Manulife Financial Corporation trades at $41.3 (market cap $68.68B). The key difference: Manulife Financial Corporation is far larger — about 2.4× Biogen Inc's market cap, and Manulife Financial Corporation pays a 3.2% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MFC | |
|---|---|---|
Market Cap | $28.34B | $68.68B |
Sector | Health | Financials |
52-Week High | $216.63 | $41.69 |
52-Week Low | $122.68 | $29.90 |
Enterprise Value | $30.62B | $65.24B |
Dividend Yield | — | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Manulife Financial (MFC) trades at $41.29, unchanged on the day, near its 52-week high. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal steady revenue growth to $53.01B in 2025 and a net income margin of 12.07%. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with 57% buy ratings. Key developments include a dividend payment and AI partnership expansions.
Outlook is cautiously optimistic with growth driven by Asia operations and AI initiatives, but risks include Q1 earnings miss and regulatory scrutiny. Valuation at P/E 16.89 and P/B 2.17 appears reasonable. Investors should monitor execution on earnings recovery and wealth management flows amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
